The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Shortly after bringing in a former FDA official to serve as its chief medical officer, Pfizer’s latest leadership appointment ...

WASHINGTON, D.C. U.S. Senate Democratic Whip Dick Durbin (D-IL) sent letters to five telehealth companies that have held ...